174 related articles for article (PubMed ID: 32897000)
1. Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.
Jin S; Muhammad N; Sun Y; Tan Y; Yuan H; Song D; Guo Z; Wang X
Angew Chem Int Ed Engl; 2020 Dec; 59(51):23313-23321. PubMed ID: 32897000
[TBL] [Abstract][Full Text] [Related]
2. Alternative mechanism of action of the DNP Pt
Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
[TBL] [Abstract][Full Text] [Related]
3. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.
Chen Y; Wang Q; Li Z; Liu Z; Zhao Y; Zhang J; Liu M; Wang Z; Li D; Han J
Dalton Trans; 2020 Apr; 49(16):5192-5204. PubMed ID: 32236281
[TBL] [Abstract][Full Text] [Related]
4. On the stability and biological behavior of cyclometallated Pt(IV) complexes with halido and aryl ligands in the axial positions.
Escolà A; Crespo M; López C; Quirante J; Jayaraman A; Polat IH; Badía J; Baldomà L; Cascante M
Bioorg Med Chem; 2016 Nov; 24(22):5804-5815. PubMed ID: 27670096
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
6. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
7. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
8. A novel series of pyrazole-platinum(II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells.
Czarnomysy R; Surażyński A; Muszynska A; Gornowicz A; Bielawska A; Bielawski K
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1006-1023. PubMed ID: 29862867
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
10. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y
Oncotarget; 2017 Apr; 8(15):24706-24718. PubMed ID: 28160557
[TBL] [Abstract][Full Text] [Related]
12. Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs.
Chen F; Wang X; Jin X; Zhao J; Gou S
Oncotarget; 2017 May; 8(19):30933-30955. PubMed ID: 28427237
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Zhang D; Reyes RM; Osta E; Kari S; Gupta HB; Padron AS; Kornepati AVR; Kancharla A; Sun X; Deng Y; Wu B; Vadlamudi R; Li R; Svatek RS; Curiel TJ
Cancer Med; 2021 Mar; 10(6):2137-2152. PubMed ID: 33626233
[TBL] [Abstract][Full Text] [Related]
14. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
16. Targeting RNA polymerase I transcription machinery in cancer cells by a novel monofunctional platinum-based agent.
Zhang ZL; Zhao CL; Chen Q; Xu K; Qiao X; Xu JY
Eur J Med Chem; 2018 Jul; 155():434-444. PubMed ID: 29908438
[TBL] [Abstract][Full Text] [Related]
17. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes.
Lorenzo J; Delgado A; Montaña ÁM; Mesas JM; Alegre MT; Rodríguez Mdel C; Avilés FX
Eur J Med Chem; 2014 Aug; 83():374-88. PubMed ID: 24980119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
